1 / 14

Diagnosis of Multiple Myeloma

This article delves into the diagnosis and initial therapy options for multiple myeloma, comparing the benefits of various immunotherapy approaches. It explores the use of Imids, PIs, Steroids, and novel agents like Blinatumumab, highlighting ongoing trials and outstanding questions in the field.

jessieg
Download Presentation

Diagnosis of Multiple Myeloma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diagnosis of Multiple Myeloma

  2. Choice of Initial Therapy More toxic Less convenient Is there a long-term benefit to more intensive up-front therapy?

  3. Summary: Initial therapy

  4. Summary: Transplant and maintenance

  5. Bone therapy: outstanding questions

  6. Imids thalidomide lenalidomide pomalidomide PIs bortezomib carfilzomib ixazomib Steroids Dexamethasone Prednisone Cytotoxics cyclophosphamide melphalan doxorubicin bendamustine HDACi panobinostat MoAbs elotuzumab daratumumab

  7. Trials at Penn for first-line therapy

  8. Choosing triplets for relapsed myeloma

  9. Summary

  10. BiTE (bispecific T cell engager) Blinatumumab FDA-approved Baeuerle, Cancer Res 2009

  11. Immunotherapy targets for myeloma

  12. Cellular therapy in MM: what’s happening in 2019

  13. Comparison of immunotherapy approaches

  14. Conclusions and challenges

More Related